Nanobiotix annual operating income
2018
2019
2020
2021
2022
2023
2024
2025
Nanobiotix Operating Income Growth & History (NANO)
Nanobiotix's operating income was −€10.8M for fiscal 2025.
View full Nanobiotix company overviewNanobiotix annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −€10.8M | €57.6M | — |
| 2024 | 2024-12-31 | −€68.4M | −€41.6M | — |
| 2023 | 2023-12-31 | −€26.8M | €19.9M | — |
| 2022 | 2022-12-31 | −€46.7M | €5.9M | — |
| 2021 | 2021-12-31 | −€52.6M | −€16.2M | — |
| 2020 | 2020-12-31 | −€36.4M | €10.4M | — |
| 2019 | 2019-12-31 | −€46.8M | −€16.7M | — |
| 2018 | 2018-12-31 | −€30.1M | — | — |
Nanobiotix operating income trends
Over the last five fiscal years, Nanobiotix's operating income increased from −€36.4M to −€10.8M, a change of €25.6M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nanobiotix source filings ↗Community posts
Nanobiotix reports final melanoma cohort results for radioenhancer combination
Nanobiotix ($NANO) reported updated Phase 1 results in 24 heavily pretreated patients with advanced cutaneous melanoma resistant to anti-PD-1 therapy. Its JNJ-1900, also called NBTXR3, was injected into a tumor before radiotherapy and subse ...
